Evidence guide · UK

Hair loss on GLP-1 medicines: what the evidence shows, and why biotin can skew blood tests

Hair loss affects about 3% to 6% of people on semaglutide or tirzepatide in trials, against about 1% on placebo. What a survey indexed on 18 November 2026 adds, why biotin is unlikely to help, and how it can distort blood tests.

Review type: research summary. This page summarises published research and product labels, cited below.

Hair shedding is a reported side effect of semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, sold for weight management in the US as Zepbound). A survey of 504 US users, indexed in PubMed on 18 November 2026, put self-reported hair changes at 38.9%. That figure is far higher than the rates in the placebo-controlled trials behind the US labels, which sit in the low single digits. Hair supplements, many of them containing biotin, are marketed to the same people, and the FDA warns that biotin can distort some blood tests.

Short answer: hair loss is more common on GLP-1 medicines than on placebo, the labels link it to weight reduction, and the NHS lists weight loss among the causes of hair loss that may be temporary. There is no good evidence that biotin helps hair in people who are not deficient, and deficiency is rare. If you do take a high-dose biotin product, tell whoever orders your blood tests, because it can make some results falsely high or falsely low.

Grades used here: Strong (consistent results from several good-quality human trials), Moderate (good trials, but few or with mixed results), Limited (small or low-quality human studies, or good studies in other groups of people), Insufficient (too little human research to judge) and Evidence of harm.

What the labels say

The US prescribing information for Wegovy (effective 18 June 2026) says hair loss in Wegovy injection trials was associated with weight reduction. In a pool of three trials, hair loss was reported by 3.3% of people on Wegovy 2.4 mg (4% of women and 0.9% of men) and by 1% on placebo (2% of women and no men). In the trial of the higher 7.2 mg dose, the figures were 6% on 7.2 mg, 3% on 2.4 mg and 1% on placebo. Hair loss appears in the label's list of most common adverse reactions.

The US prescribing information for Zepbound (effective 28 August 2026) gives hair loss rates of 5%, 4% and 5% on the 5 mg, 10 mg and 15 mg doses, against 1% on placebo. It also says hair loss was associated with weight reduction and was reported more often in women than men (7.1% against 0.5% on tirzepatide, and 1.3% against 0% on placebo). No tirzepatide-treated patients stopped treatment because of hair loss in those trials, compared with one on placebo.

The pooled trial data

A 2026 meta-analysis in Diabetes Research and Clinical Practice pooled nine interventional studies (seven randomised trials and two non-randomised studies) with 4,114 people on GLP-1 medicines. The risk of hair loss was about three times higher than with placebo (risk ratio 3.25, 95% CI 1.44 to 7.36), and the result held when the analysis was limited to randomised trials in people with overweight or obesity (3.59, 2.10 to 6.12). Across the GLP-1 groups, 3.9% reported hair loss. A tripled risk on a low baseline still means most people do not report it.

A large health-records study

A target trial emulation in the BMJ used Penn Medicine health records for adults with type 2 diabetes who started a GLP-1 medicine, an SGLT-2 inhibitor or a DPP-4 inhibitor between January 2019 and September 2024. About 12,000 GLP-1 starters in each comparison were compared with 15,221 SGLT-2 and 11,238 DPP-4 starters. GLP-1 medicines were linked to a higher risk of diagnosed hair loss than SGLT-2 inhibitors (hazard ratio 1.37, 1.08 to 1.73) and DPP-4 inhibitors (1.68, 1.28 to 2.20). The link was specific to non-scarring hair loss and weakened after a calibration step using a negative control outcome. The authors say the absolute risk is low. Observational data like these can show an association but cannot prove cause.

The November 2026 survey

The newest paper is a single-centre online survey of 504 US adults using GLP-1 or dual GLP-1/GIP medicines, run between 20 June and 15 July 2025 and indexed in PubMed on 18 November 2026. Respondents were 89.9% women, with a mean age of 52.8. Hair changes were reported by 38.9%, mainly shedding (20.8%) and thinning (19.0%), and 42.0% of those reporting shedding said it began within one to three months of starting treatment. Any skin change was reported by 38.7%, most often facial volume loss (10.9%) and sagging (8.3%). Treatment satisfaction was 92.0%.

Read the survey with care. All of its authors are employees of L'Oréal Research and Innovation USA, a cosmetics company. The changes were self-reported, with no clinical examination and no comparison group of people not taking the medicines, and the authors list recall bias, a mostly female sample and the 26.8% of respondents using compounded products among the limitations. It describes how users perceive their hair, not how much of the change the medicine causes.

Why weight loss can trigger shedding

Both labels say hair loss in the trials was associated with weight reduction. The NHS lists weight loss, illness, stress and iron deficiency among the causes of hair loss that may be temporary, and says hair loss caused by a medical condition usually stops or grows back once you have recovered. Iron deficiency is one cause worth ruling out on these medicines; the GLP-1 anaemia guide covers the evidence on iron and B12.

Hair loss on GLP-1 medicines: Moderate

Placebo-controlled trials in the labels and a meta-analysis agree that hair loss is more common on GLP-1 medicines, at rates of roughly 3% to 6% against about 1% on placebo, and it is more often reported by women. That supports a Moderate grade. Whether the risk differs between individual medicines, and how long shedding lasts, is not settled.

Biotin for hair: Limited

A 2024 review in the Journal of Clinical and Aesthetic Dermatology identified only three studies of oral biotin for hair growth or quality. The highest-quality one, a double-blind placebo-controlled trial, showed no difference between biotin and placebo. The other two, in people taking isotretinoin and in women after sleeve gastrectomy, were open to bias and did not show striking results. An earlier review of 18 case reports noted that every patient who improved on biotin had an underlying cause of poor hair or nail growth, and its authors found the evidence insufficient for supplementation in healthy people. The NIH Office of Dietary Supplements says biotin deficiency is very rare in the United States, that adults need about 30 micrograms a day, and that there is little scientific evidence for hair, skin and nail claims. No trial has studied biotin for hair loss on GLP-1 medicines. With only three human studies, two of them open to bias, the grade is Limited.

Biotin and blood tests

The FDA says biotin, often found in dietary supplements, can significantly interfere with certain lab tests and cause incorrect results that may go undetected. It has continued to receive adverse event reports of falsely low troponin results, a test used to diagnose heart attacks, and it publishes a list of troponin assays that have not addressed the problem. The NIH Office of Dietary Supplements says biotin above recommended amounts may cause false results in some tests, including thyroid hormone tests.

Guidance from the American Association for Clinical Chemistry (AACC) says biotin in multivitamins at doses up to 1 mg has not been reported to cause interference, but high-dose supplements of 5 mg or more significantly raise blood levels, which can interfere with commonly used tests. It recommends that people taking 5 to 10 mg wait at least 8 hours before a blood sample, and says some tests may need up to 72 hours. A 5 mg dose is more than 160 times the 30 micrograms adults need. A 2021 study of 524 routine samples at one UK laboratory found none at or above 10 micrograms per litre, the lowest interference threshold for one manufacturer's tests, and called the probability of interference in its patients extremely low, except for assays with the lowest thresholds.

Our view

  • Shedding after starting a GLP-1 medicine is a recognised side effect linked to weight loss, and the NHS lists weight loss among causes of hair loss that may be temporary.
  • See your doctor if hair loss is heavy, patchy, lasts many months or comes with tiredness, which can point to iron deficiency or another cause.
  • Do not expect a biotin supplement to stop GLP-1 shedding. The trial evidence does not show a benefit in people who are not deficient.
  • If you take biotin, check the dose on the label and tell the doctor or nurse before any blood test, especially a heart or thyroid test.
  • Report hair loss on a GLP-1 medicine to your prescriber, and be wary of products sold as a fix for medicine-related hair loss.

UK rules

In the UK, biotin and hair supplements are usually sold as food supplements. Food supplements are not medicinal products and should not be sold with a claim to prevent, treat or cure a medical condition, including medicine-related hair loss. Report suspected side effects of a GLP-1 medicine, including hair loss, through the MHRA Yellow Card scheme. If a food supplement makes you unwell, stop it and contact a healthcare professional; concerns about its safety, labelling or claims can be reported to your local authority, which reports food safety incidents to the Food Standards Agency.

FAQ

Does Wegovy or Mounjaro cause hair loss?

Hair loss is more common than on placebo in the trials behind the US labels: 3.3% on Wegovy 2.4 mg against 1% on placebo, and 4% to 5% on tirzepatide against 1%. Both labels link it to weight reduction, and it is reported more often by women.

Is GLP-1 hair loss permanent?

The labels do not report a regrowth rate, so there is no firm figure. The NHS says hair loss that may be temporary can be caused by weight loss, and that hair loss caused by a medical condition usually stops or grows back once you have recovered. See your doctor if it is heavy or does not settle.

Should I take biotin for hair loss on a GLP-1 medicine?

There is no trial evidence that biotin helps in this situation, and reviews do not find good evidence of a benefit for hair in people who are not deficient. High doses can also distort blood tests such as troponin and thyroid tests, so tell your doctor if you take it.

How long should I stop biotin before a blood test?

Ask the doctor or laboratory. AACC guidance suggests waiting at least 8 hours after a 5 to 10 mg dose and up to 72 hours for some tests. Do not delay emergency care to wait.

Sources

These are the documents this page relies on.

  1. Olivero JW, Paturi J, Moreau M, et al. Dermatological, trichological and quality of life consequences of GLP-1 receptor agonist-mediated weight loss: a US cross-sectional survey. J Cosmet Dermatol. 2026;25(8):e71145 (indexed in PubMed 18 November 2026)Journal of Cosmetic Dermatology (PubMed 43047060)
  2. Cheng PL, Chang HC. Glucagon-like peptide-1 receptor agonists and hair loss: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2026;237:113333Diabetes Research and Clinical Practice (PubMed 42155605)
  3. Tang H, Zhang B, Lu Y, et al. Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation. BMJ. 2026;394:e100077BMJ (PubMed 42486607)
  4. Wegovy (semaglutide) injection and tablets: US prescribing information, section 6.1 (DailyMed, effective 18 June 2026)Novo Nordisk via DailyMed, US National Library of Medicine
  5. Zepbound (tirzepatide) injection: US prescribing information, section 6.1 (DailyMed, effective 28 August 2026)Eli Lilly and Company via DailyMed, US National Library of Medicine
  6. Yelich A, Jenkins H, Holt S, Miller R. Biotin for hair loss: teasing out the evidence. J Clin Aesthet Dermatol. 2024;17(8):56-61Journal of Clinical and Aesthetic Dermatology (PubMed 39148962)
  7. Patel DP, Swink SM, Castelo-Soccio L. A review of the use of biotin for hair loss. Skin Appendage Disord. 2017;3(3):166-169Skin Appendage Disorders (PubMed 28879195)
  8. Biotin interference with troponin lab tests: assays subject to biotin interferenceUS Food and Drug Administration
  9. Li D, Ferguson A, Cervinski MA, Lynch KL, Kyle PB. AACC guidance document on biotin interference in laboratory tests. J Appl Lab Med. 2020;5(3):575-587The Journal of Applied Laboratory Medicine (doi:10.1093/jalm/jfz010)
  10. Sanders A, Gama R, Ashby H, Mohammed P. Biotin immunoassay interference: a UK-based prevalence study. Ann Clin Biochem. 2021;58(1):66-69Annals of Clinical Biochemistry (PubMed 32936669)
  11. Biotin: fact sheet for consumersOffice of Dietary Supplements, National Institutes of Health
  12. Hair lossNHS
  13. Food supplements: guidance for consumers (published 25 June 2026)GOV.UK
  14. Yellow Card: report a side effectMedicines and Healthcare products Regulatory Agency